Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026Topline Results from North American Phase 3 ...
Researchers at the University of Washington have developed a rapid test that quickly detects hepatitis C, but insurance ...
AbbVie (NYSE: ABBV) announced today that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir tablets) for the treatment of acute and chronic hepatitis C virus (HCV) infection in adults and ...
A new rapid test for hepatitis C could help identify many more patients who could be cured of the deadly disease, but its use ...
Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and CanadaC-BEYOND Topline Results Expected ...
Hepatitis C is the leading cause of chronic liver disease and liver cancer in the world and affects an estimated 51 million people globally. Though the viral infection is easily diagnosable and ...
People coinfected with HIV and hepatitis C virus remain at risk for hepatocellular carcinoma within 6 years of starting ...
Osaka, Japan - Hepatitis C virus (HCV) may cause chronic infection to the liver, which can result in irreversible liver damage and liver cancer. How HCV manages to evade the immune system to infect ...
When managing patients with hepatitis C virus (HCV), initiating treatment of the infection promptly is more important than determining the severity of their liver disease with the customary staging ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback